【摘要】 出血是目前临床抗栓药物防治最主要、最常见的并发症。近年来,有关凝血因子XI(FXI)与血栓性疾病发生相关的临床资料、FXI基因敲除动物或抑制FXI的抗栓实验均表明FXI是出血风险小的抗栓防治新靶点,针对FXI靶点的抗栓药物出血副作用小。更多还原

【Abstract】 Thromboembolic diseases are major health problems worldwide,and remain the leading cause of mortality and disability at present. Bleeding is the most important complication of antithrombotic therapy for thromboembolism,therefore research and development of new antithrombotic drugs with lowered bleeding risk is a significant medical need. The data that elevated plasma levels of FXI are associated with thromboembolic diseases,severe FXI deficiency reduced incidence of DVT and ischemic stroke,and FXI deficiency or inhibition in animals shows protective effects against thrombus formation supporting FXI as a novel antithrombotic target with lowered bleeding risk. This paper reviews the progress on FXI as a novel antithrombotic target and the inhibitors target FXI.更多还原